Incidence of Microvascular Outcomes among Type 2 Diabetes Patients Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Cohort Study Using German Electronic Medical Records

Trial Profile

Incidence of Microvascular Outcomes among Type 2 Diabetes Patients Treated with Vildagliptin vs. Sulfonylurea: A Retrospective Cohort Study Using German Electronic Medical Records

Completed
Phase of Trial: Phase IV

Latest Information Update: 01 Sep 2016

At a glance

  • Drugs Vildagliptin (Primary) ; Sulfonylureas
  • Indications Diabetic complications; Diabetic foot ulcer; Diabetic nephropathies; Diabetic neuropathies; Diabetic retinopathy; Type 2 diabetes mellitus
  • Focus Therapeutic Use
  • Most Recent Events

    • 01 Sep 2016 Results assessing incidence of microvascular complications published in the Diabetes Therapy (2016).
    • 28 Jul 2015 New trial record
    • 09 Jul 2015 Primary endpoint has not been met. (Significantly lower incidence of diabetic foot ulcer with vildagliptin than with a sulfonylurea)
Restricted Access

Oops, it looks like you don’t have a valid subscription to this content. To gain full access to the content and functionality of the AdisInsight database try one of the following.

  • with a username/password associated to an account with a valid subscription
  • Contact your organization’s admin about adding this content to your AdisInsight subscription
  • Request a trial

If you are a subscriber to this content then contact us at AsktheExpert.AdisInsight@springer.com so we can help.

Back to top